<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1667">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393233</url>
  </required_header>
  <id_info>
    <org_study_id>RHUMACOVID ( 29BRC20.0110)</org_study_id>
    <nct_id>NCT04393233</nct_id>
  </id_info>
  <brief_title>Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation</brief_title>
  <acronym>RHUMACOVID</acronym>
  <official_title>Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among
      patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune
      diseases, there may be legitimates interrogations about the appropriateness of continuing
      treatment, without modification, in the current context. Most patients with Juvenile
      Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease
      modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal
      anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this
      issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis
      has been modified in relation to the actual sanitary crisis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Anticipated">May 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis</measure>
    <time_frame>1 Day</time_frame>
    <description>Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>COVID</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatoid arthritis patients with ongoing DMARD therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid arthritis satisfying ACR/EULAR criteria

          -  Ongoing DMARD therapy

        Exclusion Criteria:

          -  Inhability to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dewi GUELLEC</last_name>
    <phone>+33298347264</phone>
    <email>dewi.guelle@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie Devauchelle</last_name>
    <phone>+33298347264</phone>
    <email>valerie.devauchelle-pensec@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dewi Guellec</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning one month and ending five years following the end study</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

